Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

With high regard for China's vast market potential and dynamic innovation ecosystem, Opella, Sanofi's consumer healthcare ...

[Photo provided to chinadaily.com.cn] With high regard for China's vast market potential and dynamic innovation ecosystem, Opella, Sanofi's consumer healthcare business, is expected to leverage ...

debt sale to finance Clayton Dubilier & Rice’s purchase of a stake in Sanofi’s (SNY) consumer health division Opella, Eleanor Duncan of Bloomberg reports. The sale includes EUR 5.45B ...

The debt package for the unit, which is called Opella, was one of the most hotly anticipated financing deals to come to market this year in Europe and the US. It included €5.2 billion-equivalent ...

Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline story, it believes this is somewhat reflected at ...

Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to $1.9B. The French pharmaceutical company will acquire DR-0201, a CD20 ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...

The debt package for the unit, which is called Opella, was one of the most hotly ... to CD&R last year so the firm could buy part of Sanofi’s consumer arm. But they had to keep the debt on ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.

March 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, ...